Indaptus Therapeutics company info

What does Indaptus Therapeutics do?
Indaptus Therapeutics (NASDAQ:INDP) is a biopharmaceutical company dedicated to developing novel therapies that target unmet needs in the treatment of infectious diseases and oncology. By harnessing the body's own immune system, Indaptus aims to provide innovative solutions that can lead to better patient outcomes and a significant impact on current treatment paradigms. The company is focusing on advancing its pipeline of decoy therapeutics, which are designed to engage and activate the immune response against cancer cells and pathogens. One of the main objectives of Indaptus is to bring these promising therapies through clinical trials and, ultimately, to patients in need, demonstrating their commitment to improving health and transforming lives through scientific innovation.
Indaptus Therapeutics company media
Company Snapshot

Is Indaptus Therapeutics a public or private company?

key
Ownership
Public

How many people does Indaptus Therapeutics employ?

people
Employees
7

What sector is Indaptus Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Indaptus Therapeutics?

location pin
Head Office
New York, United States

What year was Indaptus Therapeutics founded?

founded flag
Year Founded
2021
What does Indaptus Therapeutics specialise in?
/Therapeutic Development /Stem Cell /Cell Therapy /Cancer Treatments /Regenerative Medicine /Innovative Research

What are the products and/or services of Indaptus Therapeutics?

Overview of Indaptus Therapeutics offerings
Decoy20 is a dual-function immunotherapy for treating various cancers and infectious diseases by activating the patient's immune system to target and eliminate diseased cells.
The development of novel decoy-based therapeutics aims at harnessing the body's natural defense mechanisms to combat a range of pathologies, including chronic inflammatory conditions.
Exploratory research into the synergistic effects of combining their decoy technology with existing treatments to enhance efficacy and overcome resistance in hard-to-treat diseases.
Advanced studies on the mechanism of action of their decoy platforms to further refine and expand therapeutic applications and improve patient outcomes.
Initiation of preclinical studies to validate the safety and effectiveness of their pipeline products, ensuring a solid foundation for future clinical trials.
Outreach and collaboration efforts with academic and industry partners to accelerate the development of their therapeutic programs and expand their potential impact on patient care.

Who is in the executive team of Indaptus Therapeutics?

Indaptus Therapeutics leadership team
  • Mr. Jeffrey A. Meckler
    Mr. Jeffrey A. Meckler
    CEO & Director
  • Mr. Walt Addison Linscott Esq.
    Mr. Walt Addison Linscott Esq.
    Chief Operating Officer
  • Dr. Michael J. Newman Ph.D.
    Dr. Michael J. Newman Ph.D.
    Founder, Chief Scientific Officer & Director
  • Mr. Nir  Sassi
    Mr. Nir Sassi
    CFO, Secretary & Treasurer
  • Dr. Roger J. Waltzman M.B.A., M.D.
    Dr. Roger J. Waltzman M.B.A., M.D.
    Chief Medical Officer